Tempus AI, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Eric Paul Lefkofsky
- Full Time Employees
- 3,800
- Sector
- Technology services
- Industry
- Packaged software
- Address
- 600 West Chicago Avenue Chicago IL United States 60654
- IPO Date
- Jun 14, 2024
- CIK
- 0001717115
- Website
- tempus.com
- Similar Companies
- Business
- Tempus AI, Inc. operates as an innovative healthcare technology firm, dedicated to transforming patient care through the application of artificial intelligence. The company specializes in delivering comprehensive genomic sequencing diagnostics, including next-generation sequencing, polymerase chain reaction profiling, and advanced molecular pathology testing to a broad spectrum of healthcare entities. These clients include medical providers, pharmaceutical manufacturers, biotechnology innovators, and research institutions. The organization provides a suite of advanced platforms such as Tempus Lens, designed for scientists to explore, access, and analyze de-identified clinical, molecular, and imaging data, and Tempus Hub, a streamlined desktop and mobile interface for managing test orders and patient results. Their offerings also encompass predictive algorithmic tests, like Algos and Next, tailored for oncology and other therapeutic areas, as well as Trials, a service that facilitates patient matching for clinical studies. Tempus AI generates revenue primarily through its genomic testing services, data licensing, and clinical trial solutions. The company notably expanded its reach by going public on Nasdaq in June 2024 under the ticker TEM. Recent strategic developments include the November 2024 acquisition of Ambry Genetics, a $600 million deal, and the formation of SB Tempus, an AI healthcare joint venture in Japan with SoftBank. In April 2025, Tempus AI, AstraZeneca, and Pathos AI announced multi-year agreements, including $200 million in data licensing and model development fees to Tempus, to co-develop a significant multimodal foundation model in oncology, building on an earlier 2021 partnership. Further collaborations in 2025 include a partnership with Illumina for genomic testing integration and research alliances with Northwestern University for Alzheimer's disease and the Institute for Follicular Lymphoma Innovation. Headquartered in Chicago, Illinois, Tempus AI was established in 2015 and remains at the forefront of leveraging large-scale multimodal data and AI to accelerate precision medicine, with a significant presence among U.S. oncologists and top biopharma companies.
Company News
The $1.5 Billion Question Facing Tempus AI Ahead of Nov. 2 Earnings
Tempus AI (TEM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Tempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling
Tempus AI: Less Risky Than When I Said Buy
Tempus Expands Strategic Collaboration with Bristol Myers Squibb
Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer's Disease and Other Neurological Conditions
Tempus AI: Moderna's New Cancer Vaccine Partner Is The Pick Of The AI Biotech Bunch
How Tempus AI Built a Defensible Data Moat in Precision Healthcare
Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC
Here's How Tempus AI Demonstrates Improving Operating Leverage
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC
Tempus to Report Third Quarter 2026 Financial Results on November 2
Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases
Tempus AI Expands Strategic Collaborations to Drive Future Growth
Should You Buy, Hold or Sell Tempus AI Stock Amid AI Boom?
Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure
Tempus Announces Multi-Year Collaboration with Moderna and Merck
Tempus Announces Multi-Year Collaboration with Moderna and Merck
Here's How Tempus AI is Capitalizing on AI-ECG Market Growth